This trial is evaluating whether Repetitive Transcranial Magnetic Stimulation (rTMS) will improve 2 primary outcomes, 7 secondary outcomes, and 1 other outcome in patients with Anxiety Disorders. Measurement will happen over the course of Immediately Pre-Stimulation and Immediately Post-Stimulation (Approx. 30 minutes between assessments).
This trial requires 80 total participants across 2 different treatment groups
This trial involves 2 different treatments. Repetitive Transcranial Magnetic Stimulation (rTMS) is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Recent findings reported positive results of tDCS use in anxiety disorder, but not depression. The effectiveness of tDCS in anxiety is not yet verified. However, if proven, the use of tDCS in anxiety disorder may be an effective short-term treatment option.
Anxiety symptoms include a sense of tension and worrying about physical sensations. They are usually accompanied by an increased level of arousal. There are a number of psychological tests that can help with differential diagnosis of anxiety disorders.
Anxiety may result from a biological imbalance, including neurotransmitter malfunction or genetic alterations. The biological basis of anxiety may in fact not be well understood, since it affects almost every organ on the body. It can also result from life situations, including negative experiences, and cognitive distortions. Anxiety symptoms are not universal, as they are also influenced through a person's personality. Anxiety is one of the most commonly overlooked health conditions.\n
Based on the positive results of a recently conducted double-blind randomized placebo-controlled study on treatment of panic disorder and its subtype agoraphobia with the anxiolytic drug alprazolam, we suggest that there may be a basis for the treatment of anxiety disorders.
Anxiety disorders are a very common medical condition with both moderate and severe repercussions. Physicians should be alert to anxiety symptoms. Anxiety symptoms often represent a risk factor for anxiety disorders, such as panic attacks for which the most efficacious pharmacological treatments exist.
Anxiety disorders (including specific phobias and specific post-traumatic stress disorders) are prevalent and disabling in the US population. The rate of diagnosis appears to continue. Anxiety disorders are associated with high rates of utilization of health care and psychotherapy. Many patients are dissatisfied with their treatment.
There are some treatments that may be used with people who have anxiety disorders. The first thing to consider with people with anxiety disorders is to help them learn skills to cope with anxiety so they can be better treated. It is also important to have treatments to help people overcome the anxiety. These are available as one-on-one sessions with a therapist. Cognitive behavioral therapy works in some cases where the problem is not bad enough to go to seeing a doctor, and the problem can be reduced or eliminated with help of the sessions of a therapist.
We can conclude that rtms at a very low frequency is not associated with an increased risk of side effects compared with the placebo group. Although there were no adverse effects or problems in most of the reported side effects, the high percentage of patients who reported headache has been taken into account. The observed headache resolves after receiving the stimulation, and there is no need to treat this complaint after the stimulation is finished. Further studies in patients using rtms for long term treatment of chronic pain are awaited with more detail. Copyright © 2016 John Wiley & Sons, Ltd.
The lifetime prevalence of anxiety disorder is estimated to be 1.1-1.2% in the general U.S. population. About one in twelve adults (7%) had a lifetime diagnosis of anxiety disorder at some point in his or her life. Men and women differ in their lifetime rates of diagnosis: about one in six women (15%) had a lifetime diagnosis of an anxiety disorder.
In a recent study, findings are consistent with family environmental transmission of anxiety disorders. This implies an important role for both genetic and familial environmental risk factors, which contribute to the clinical and epidemiological differences between families.
Anxiety disorders are a common problem in primary care, but the problem may not always be treated in a consistent manner, which could potentially lead to patient dissatisfaction. This pilot study aims to examine some of these issues, and provide possible solutions for patients.